PORTICO NG Approval Study (Navitor Titan cohort only), CIP rev D

  • Research type

    Research Study

  • Full title

    Portico NG Approval Study - Evaluation of the Portico™ NG Transcatheter Aortic Valve in High and Extreme Risk Patients with Symptomatic Severe Aortic Stenosis

  • IRAS ID

    314653

  • Contact name

    Rebecca Malpass

  • Contact email

    rebecca.malpass@abbott.com

  • Sponsor organisation

    Abbott

  • Clinicaltrials.gov Identifier

    NCT04011722

  • Clinicaltrials.gov Identifier

    PORTICO NG Study, CI/2019/0036

  • Duration of Study in the UK

    5 years, 4 months, 30 days

  • Research summary

    The purpose of this research study is to collect data on the Portico NG TAVI system (Portico NG Transcatheter Aortic Valve, FlexNav delivery system and Portico NG Loading System), which is used to treat heart valve disease, and to support commercial approval of the device.

    This new application is being made at the request of the MHRA to obtain approval for the larger size heart valve to be included in this study (Navitor Titan- 35mm). The additional valve has been included in CIP revision D, both tracked change and clean versions have been included with this application.

  • REC name

    HSC REC B

  • REC reference

    22/NI/0086

  • Date of REC Opinion

    30 Jun 2022

  • REC opinion

    Further Information Favourable Opinion